Active Stocks
Thu Apr 18 2024 15:59:07
  1. Tata Steel share price
  2. 160.00 -0.03%
  1. Power Grid Corporation Of India share price
  2. 280.20 2.13%
  1. NTPC share price
  2. 351.40 -2.19%
  1. Infosys share price
  2. 1,420.55 0.41%
  1. Wipro share price
  2. 444.30 -0.96%
Business News/ Industry / Manufacturing/  Medicine sales rise 14.5% in Nov, Indian pharma firms lead growth
BackBack

Medicine sales rise 14.5% in Nov, Indian pharma firms lead growth

Top 10 drug manufacturers posted sales growth in the range of 12.6-17.9% in November
  • While sales of drugs under national list of essential medicines, grew 15.2% to ₹1,245 cr, that of medicines not under price control grew 14.6% to ₹10,866 crores
  • India’s largest firm Sun Pharma posted a 14.5% growth in sales for the month to ₹1,035 crore (Photo: Pradeep Gaur/Mint)Premium
    India’s largest firm Sun Pharma posted a 14.5% growth in sales for the month to 1,035 crore (Photo: Pradeep Gaur/Mint)

    NEW DELHI : A low base coupled with an early festival season helped pharmaceutical sales rise 14.5% year-on-year to 12,624 crore in November, with sales of most Indian drug manufacturers outpacing their foreign peers, data from market research firm AIOCD-AWACS showed.

    The market research firm said the sales were “one of the best growths seen in more than 32 months", and attributed it to the weak 7% sales growth seen in the corresponding month last year, as well as the entire festival season ending in October itself this year. Last year, Diwali was in November.

    Among the top 10 drug manufacturers, Sun Pharmaceutical Industries, Cipla, Cadila Healthcare, Lupin, Mankind Pharmaceuticals, Alkem Laboratories and Torrent Pharmaceuticals posted sales growth in the range of 12.6-17.9% in November.

    India’s largest firm Sun Pharmaceutical posted a 14.5% growth in sales for the month to 1,035 crore, while the Abbott group, the largest multinational firm and India’s second-largest, posted 12% growth to 779 crore.

    While sales of drugs under national list of essential medicines, which come under price control, grew 15.2% to 1,245 crores, that of medicines not under price control grew 14.6% to 10,866 crores.

    Among the major therapy segments, anti-infective and respiratory drug sales led the growth with 17.0% and 19.7% respectively in November.

    Over the last few years, medicines in anti-diabetic and cardiac segments have led sales growth, reflecting their increasing cases among the Indian population. For the year ending November, these two segments were the only ones in the top-10 therapies that grew in double digits.

    For the year ending November, sales in the Indian pharmaceutical market grew 9.8% at 1.39 lakh crore, with Lupin, Mankind Pharma, Intas Pharmaceuticals and Alkem Laboratories leading the growth.


    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Industry News, Banking News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 09 Dec 2019, 10:27 AM IST
    Next Story footLogo
    Recommended For You
    Manufacturing Stocks
    ₹608.751.26%
    ITC
    ₹425.95-1.64%
    ₹2,934.45-0.21%
    ₹1,536.95-0.86%
    ₹160.05-0.03%
    Switch to the Mint app for fast and personalized news - Get App